We interviewed a Lymphoma expert on his opinion of marketed drugs and the pipeline for treatment of Follicular Lymphoma and other hematological cancers.

If you are a KOL Insight Subscriber, please access this report here, in our KOL Insight portal (Subscribers only).

Highlights

• KOL thought that single-agent rituximab is underutilized as first-line therapy in advanced stage Follicular Lymphoma.
• KOL thought that obinutuzumab may be a better antibody than rituximab in Follicular Lymphoma, depending on the situation.
• There is no evidence of meaningful benefit in first-line use of vaccines in Follicular Lymphoma.
• The jury is going to be out for a long time on CAR-T cells in Lymphoma.
• PD-1 targeted therapy is going to be approved for Hodgkin’s Lymphoma, but it’s not going to be a billion-dollar market. There isn't a big enough patient population.

BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.

For our disclosures, please read the BioMedTracker Research Standards.